# Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

> **NCT05164055** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Genzyme, a Sanofi Company** · enrollment: 17 (actual)

## Conditions studied

- Glycogen Storage Disease Type II

## Interventions

- **DRUG:** Avalglucosidase alfa (GZ402666)

## Key facts

- **NCT ID:** NCT05164055
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-11
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164055, "Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05164055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*